Anteris Technologies (AVR) Option Scheme Meeting summary
Event summary combining transcript, slides, and related documents.
Option Scheme Meeting summary
8 Jul, 2026Opening remarks and agenda
Meeting convened for Anteris option holders to consider the Option Scheme of arrangement, with both in-person and online participation enabled.
The meeting was opened after confirming a quorum and welcoming attendees, including board members, legal advisors, and registry representatives.
The agenda focused solely on the Option Scheme resolution, as outlined in the Scheme Booklet and Supplementary Scheme Booklet.
Board and executive committee updates
Board members and key executives were introduced, with attendance both in person and online.
The board unanimously recommended voting in favor of the Option Scheme, subject to the independent expert's ongoing positive assessment.
All directors holding options indicated their intention to vote in favor of the resolution.
Strategic initiatives and plans
The Option Scheme proposes canceling existing options and issuing equivalent securities in Anteris Technologies Global Corp (ATGC), a Delaware-incorporated entity.
If approved, each option holder will receive one ATGC option for every Anteris option held on the record date.
The scheme is part of a broader corporate restructuring, subject to court approval and regulatory conditions.
Latest events from Anteris Technologies
- Q2 2026 featured global trial expansion, U.S. Medicare reimbursement, and strong cash growth.AVR
Q2 2026 TU - Shareholders considered and voted on a US redomicile scheme, with board and expert support.AVR
Share Scheme Meeting - Pre-commercial heart device company targets U.S. IPO to fund pivotal trials amid high growth potential and risk.AVR
Registration filing - Raising $90.6M to fund heart valve trials, but faces ongoing losses and high risk.AVR
Registration filing - Stockholders to vote on ASX waiver for new securities issuances and possible meeting adjournment.AVR
Proxy filing - 2024 net loss rose to $76M, cash insufficient for 12 months, additional funding required.AVR
H2 2024 - US IPO, clinical milestones, and strong R&D focus marked a pivotal year.AVR
AGM 2025 - Operating losses widened as PARADIGM Trial preparations accelerated and cash fell to $28.4M.AVR
Q2 2025 TU - Net loss rose 36% to $21.9M as R&D and trial costs surged, straining cash reserves.AVR
Q1 2025